Although pediatric patients were rarely included in interventional trials, pediatric patients frequently developed hidradenitis suppurativa (HS). For a study, researchers sought to pinpoint possible patient features and inclusion standards for upcoming pediatric HS research; a dual analysis of a pediatric HS cohort and conventional eligibility criteria in adult trials was conducted.

The prospectively gathered data registry from an HS clinic served as the foundation for this cross-sectional and descriptive investigation. Additionally, they searched 125 HS studies from the database and examined data from 61 systemic interventional HS medication trials.

In 81 pediatric individuals, there were 2.3 mean abscesses and inflammatory nodules (ANs), compared to 5.0 in adults, with the majority having Hurley stage I (39.5%, 32/81) or II (55.6%, 45/81). Patients needed to be Hurley stage II/III with AN count of ≥3 for the majority of clinical studies.

It was crucial to take into account how baseline traits affect recruitment and illness evaluation when designing clinical trials for pediatric HS. Often utilized adult trial qualifying standards may substantially hamper the recruitment of children. The primary drawback of the study was the comparatively smaller pediatric sample size, despite the huge adult sample size in the registry.